NL-TIRZ
Bundle & Save
| Quantity | Discount |
|---|---|
| 1 - 3 | 0% |
| 4 - 5 | 5% |
| 6 - 7 | 8% |
| 8 + | 10% |
| Quantity | Discount |
|---|---|
| 1 - 3 | 0% |
| 4 - 5 | 5% |
| 6 - 7 | 8% |
| 8 + | 10% |
Description
NL-TIRZ is a tirzepatide research analog designed for laboratory investigation of dual incretin receptor signaling. Tirzepatide is studied as a dual GIP and GLP-1 receptor agonist model, making it useful in preclinical research related to metabolic regulation, glucose signaling, insulinotropic pathway interaction, lipid metabolism, and body-composition pathway modeling.
This compound is intended strictly for in vitro and preclinical laboratory research.
Specifications
Product Classification: Research-Use-Only (RUO)
Total Content: 30 mg lyophilized powder per vial
Compound: Tirzepatide research analog
Form: Sterile lyophilized peptide compound
Purity: ≥99%
Storage: Store at −20 °C, protected from light
Packaging: Glass vial in protective sleeve
Applications
Intended for preclinical laboratory research only, including:
• GLP-1 receptor signaling models
• GIP receptor pathway research
• Dual incretin receptor pathway analysis
• Glucose-regulatory signaling experiments
• Metabolic pathway interaction studies
• Lipid metabolism research models
• Comparative incretin analog research
Warning
Not for human or animal use. For research purposes only.
Scientific Report
Abstract
Tirzepatide is a synthetic peptide analog investigated for dual activity at GIP and GLP-1 receptor pathways. NL-TIRZ is designed for controlled laboratory research into incretin receptor signaling, receptor interaction, glucose pathway modulation, metabolic regulation, lipid metabolism, and downstream cellular responses associated with dual incretin receptor activation.
Mechanistic Pathway
NL-TIRZ is designed around dual incretin receptor pathway modeling.
GIP Receptor Pathway
- Supports research into GIP-associated signaling
• Used in insulinotropic and metabolic pathway models
• Helps study receptor interaction in incretin systems
Effect: Provides a model for GIP receptor activity within dual-incretin research systems.
GLP-1 Receptor Pathway
- Supports investigation of incretin signaling
• Used in glucose-regulatory pathway models
• Studied for downstream metabolic signaling effects
Effect: Enables research into GLP-1 receptor contribution to dual incretin pathway activity.
Pharmacokinetics / Research Profile
| Compound | Pathway | Research Notes |
| Tirzepatide analog | GIPR / GLP-1R | Dual incretin receptor agonist model for metabolic pathway research |
Dosing Models in Research
Used only in controlled in vitro and preclinical research models to study receptor signaling and metabolic pathway response. No human or animal-use instructions are provided.
Preclinical Research Highlights
- Studied as a dual incretin receptor pathway model
• Used in glucose signaling and metabolic regulation research
• Supports comparative studies with GLP-1-only and triple-agonist models
• Relevant to lipid metabolism and insulinotropic pathway studies
• Useful for evaluating receptor interaction and downstream signaling response
Conclusion
NL-TIRZ offers a research-use-only model for studying dual GIP and GLP-1 receptor pathway activation. Its dual incretin signaling profile supports preclinical investigation into metabolic regulation, glucose pathway signaling, lipid metabolism, receptor interaction, and downstream cellular response models.
